EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The predictive value of immunohistochemistry for MYC, BCL2, and BCL6 in fluorescence in situ hybridization in aggressive mature B-cell lymphomas and re-evaluation according to the 5th edition of the World Health Organization classification: A single-center 9-year experience

Nuray Bassullu, Fatma Tokat, Irem Guvendir, Cansu Gokpinar, Tulay Tecimer

Indian Journal of Pathology and Microbiology · 2026

DOI: 10.4103/ijpm.ijpm_60_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Pathology and Microbiology, 2026. Verfasst von Nuray Bassullu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Umraniye Training and Research Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: In Situ Hybridization, Fluorescence, Proto-Oncogene Proteins c-bcl-6, Proto-Oncogene Proteins c-bcl-2, Immunohistochemistry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse large B-cell lymphoma/High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations (DLBCL/HGBL-MYC/BCL2) represent a distinct and rare diagnostic category in 5 th Edition World Health Organization (WHO-HAEM5) classification. Aim and Materials and Methods: In this study, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were used to evaluate the frequency of MYC, BCL2, and BCL6 expression and translocations in DLBCL, HGBL, and Burkitt lymphoma (BL) over a 9-year period at a single center.

Results

In our study of 287 aggressive mature B-cell lymphoma (AMBCL) cases, the WHO-HAEM5 classification identified 55.1% as DLBCL, 21.6% as BL, 15.6% as HGBL-NOS, and 7.7% as DLBCL/HGBL-MYC/BCL2. Following molecular analysis, 1.7% of DLBCL cases were reclassified as HGBL-NOS (MYC/BCL6) and 8% as DLBCL/HGBL-MYC/BCL2. AMBCL cases, 38.5% were reclassified as BL, 10.2% DLBCL/HGBL-MYC/BCL2, and 51.3% as HGBL-NOS. Additionally, 5.9% of BL cases were reclassified as HGBL-NOS. Among 287 cases, MYC and BCL2 overexpression significantly correlated with MYC-FISH and BCL2-FISH ( P < 0.001). While BCL6-IHC was observed in all rearranged cases, it showed no significant correlation with BCL6-FISH ( P = 0.807). In our study, MYC-IHC demonstrated a sensitivity of 88.66%, a specificity of 31.55%, a positive predictive value (PPV) of 42.79%, and a negative predictive value (NPV) of 82.81% for detecting MYC-FISH. BCL2-IHC showed 100% sensitivity, 47.22% specificity, 38.71% PPV, and 100% NPV for BCL2-FISH. Similarly, BCL6-IHC achieved 100% sensitivity, 10% specificity, 19.40% PPV, and 100% NPV for BCL6-FISH.

Conclusions

Our study provides a comprehensive assessment of the spectrum of MYC, BCL2, and BCL6 rearrangements based on FISH and IHC analysis results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

In Situ Hybridization, FluorescenceProto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-bcl-2ImmunohistochemistryProto-Oncogene Proteins c-mycLymphoma, B-CellLymphoma, Large B-Cell, DiffuseHumansFemaleMiddle AgedMaleAdultWorld Health OrganizationAgedPredictive Value of TestsAdolescentAged, 80 and overYoung AdultTranslocation, Genetic

Stichwörter der Autor:innen

Aggressive mature B-cell lymphomasBCL2BCL6 rearrangements and protein expressionMYC

Substanzen

Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-bcl-2BCL6 protein, humanProto-Oncogene Proteins c-mycBCL2 protein, humanMYC protein, human

Autor:innen und Institutionen

  • Department of Pathology, Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Department of Pathology, Acibadem University, Istanbul, Turkey.
  • Department of Pathology, Kartal Lütfi Kırdar Training and Research Hospital, Istanbul, Turkey.
  • Medical Student, University of Health Sciences, Istanbul, Turkey.
  • Department of Pathology, Acibadem Health Group Central Laboratory, Istanbul, Turkey.

Zitieren

APA

Bassullu, N., Tokat, F., Guvendir, I., Gokpinar, C., & Tecimer, T. (2026). The predictive value of immunohistochemistry for MYC, BCL2, and BCL6 in fluorescence in situ hybridization in aggressive mature B-cell lymphomas and re-evaluation according to the 5th edition of the World Health Organization classification: A single-center 9-year experience. Indian Journal of Pathology and Microbiology. https://doi.org/10.4103/ijpm.ijpm_60_25

Vancouver

Bassullu N, Tokat F, Guvendir I, Gokpinar C, Tecimer T. The predictive value of immunohistochemistry for MYC, BCL2, and BCL6 in fluorescence in situ hybridization in aggressive mature B-cell lymphomas and re-evaluation according to the 5th edition of the World Health Organization classification: A single-center 9-year experience. Indian Journal of Pathology and Microbiology. 2026. doi:10.4103/ijpm.ijpm_60_25

BibTeX
@article{Bassullu2026,
  author = {Bassullu, Nuray and Tokat, Fatma and Guvendir, Irem and Gokpinar, Cansu and Tecimer, Tulay},
  title = {The predictive value of immunohistochemistry for MYC, BCL2, and BCL6 in fluorescence in situ hybridization in aggressive mature B-cell lymphomas and re-evaluation according to the 5th edition of the World Health Organization classification: A single-center 9-year experience},
  journal = {Indian Journal of Pathology and Microbiology},
  year = {2026},
  doi = {10.4103/ijpm.ijpm_60_25}
}
Kostenlos starten →